Cellino’s regenerative medicine tie-up with Matricelf is a step forward for longevity

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Progress in spinal cord injury lays the foundation for regenerative therapies that ‘target aging and chronic disease at a cellular level.’

A new partnership between Cellino and Matricelf, which aims to create personalized regenerative therapies for the treatment of spinal cord injuries, has generated patient-specific neural tissues with the potential to restore lost function. Combining advanced stem cell technology with 3D tissue engineering, the collaboration is a step towards addressing age-related degeneration and chronic conditions.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3553

Matricelf

Longevity level(s):

  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Matricelf is a preclinical-stage biotechnology company specializing in personalized regenerative medicine through autologous 3D tissue engineering. The company develops patient-specific engineered neural implants derived from induced pluripotent stem cells (iPSCs) and extracellular matrix to address severe neurological injuries, with its lead program targeting spinal cord injury—a condition affecting hundreds of thousands globally with no curative treatment. By leveraging proprietary nanotechnology-based tissue regeneration, Matricelf aims to deliver one-time curative therapies that restore function and independence in patients with devastating neurological conditions. The company's platform technology has demonstrated compelling safety and functional recovery in FDA-accepted animal models, positioning it toward first-in-human clinical trials. Matricelf's broader vision extends beyond spinal cord injury to stroke, traumatic brain injury, and cardiovascular and retinal diseases.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE